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Abstract Mycobacterium tuberculosis is the leading worldwide cause of death due to a single
infectious agent. Existing anti-tuberculous therapies require long treatments and are complicated
by multi-drug-resistant strains. Host-directed therapies have been proposed as an orthogonal
approach, but few have moved into clinical trials. Here, we use the zebrafish-Mycobacterium
marinum infection model as a whole-animal screening platform to identify FDA-approved, host-
directed compounds. We identify multiple compounds that modulate host immunity to limit
mycobacterial disease, including the inexpensive, safe, and widely used drug clemastine. We find
that clemastine alters macrophage calcium transients through potentiation of the purinergic
receptor P2RX7. Host-directed drug activity in zebrafish larvae depends on both P2RX7 and
inflammasome signaling. Thus, targeted activation of a P2RX7 axis provides a novel strategy for
enhanced control of mycobacterial infections. Using a novel explant model, we find that clemastine
is also effective within the complex granulomas that are the hallmark of mycobacterial infection.
DOI: https://doi.org/10.7554/eLife.39123.001
Introduction
Tuberculosis killed approximately 1.6 million people in 2017, with around 10 million new active cases
(World Health Organization, 2018). The continued difficulty in treatment arises, in large part, from
long and relatively complex treatment regimens, currently requiring at least 6 months of treatment
with multiple antibiotics (World Health Organization, 2018). Failures in treatment and poor patient
adherence have driven the emergence of drug-resistant strains that present further therapeutic and
public health challenges. Host-directed therapies (HDTs) are a new conceptual approach designed
to enhance host-mediated clearance of bacteria or limit immunopathology rather than targeting bac-
terial processes directly (Clatworthy et al., 2018; Hawn et al., 2013). By targeting host processes,
HDTs present an orthogonal approach to existing antibiotics. Notably, they avoid the danger of
commonly arising bacterial mutations that eliminate binding of the drug to a bacterial target.
Although a number of potential HDTs for tuberculosis (TB) have been identified in cell-culture-based
models and directed animal studies, few have advanced to clinical trials (Clatworthy et al., 2018;
Hawn et al., 2013).
The complex lifestyle of Mtb renders it particularly amenable to host-directed therapies at multi-
ple points in its lifecycle, providing a number of druggable host targets (Stanley et al., 2014;
Sundaramurthy et al., 2013). Once inside host macrophages, Mtb evades and exploits
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macrophage-specific defense mechanisms, induces formation of characteristic aggregates called
granulomas (Paga´n and Ramakrishnan, 2018), and can persist in the face of an active immune
response (Philips and Ernst, 2012). Virulent mycobacteria actively evade a number of cell-autono-
mous defense pathways (Philips and Ernst, 2012); mycobacteria have been reported to inhibit
phagolysosome fusion (Tan and Russell, 2015), manipulate cell death pathways for their own sur-
vival (Srinivasan et al., 2014), mediate resistance to oxidative stress (Nambi et al., 2015), as well as
survive at low pH in fully acidified phagolysosomes (Levitte et al., 2016). In addition, pathogenic
mycobacteria reside within specialized host structures called granulomas, a unique niche in which
bacterial populations are recalcitrant to killing due to changes in bacterial physiology as well as
reduced immune cell and antibiotic access (Dartois, 2014). Most broad screens for host-directed
therapies have been limited to cell culture. While providing insight into cell-autonomous activities of
potential host-directed drugs, cell culture platforms lack the multicellular interactions and complex
environment present during mycobacterial disease in vivo.
Zebrafish are natural hosts of Mycobacterium marinum, one of the closest relatives of the Mtb
complex (Tobin and Ramakrishnan, 2008). M. marinum and Mtb share conserved virulence loci and
induce similar host immune responses and pathology, including the formation of granulomas
(Davis et al., 2002). Genes identified in zebrafish as determinants of mycobacterial disease progres-
sion have also been associated with disease severity and outcome in humans (Thuong et al., 2017;
Tobin et al., 2012). Because zebrafish larvae are optically transparent, both pathogen and host pro-
cesses can be imaged in vivo in a natural host. M. marinum infection of larval zebrafish recapitulates
key aspects of tuberculosis pathogenesis (Davis et al., 2002). In addition, the zebrafish larva’s small
size and relative permeability to small molecules allow for chemical genetic screening in the context
of whole animals (MacRae and Peterson, 2015). Here, we used the zebrafish-M. marinum model to
perform a chemical screen in whole animals for host-directed therapies during mycobacterial
infection.
We identify a number of host-directed therapies with in vivo efficacy against mycobacterial infec-
tion. Among these is clemastine, a well-tolerated, broadly available, FDA-approved drug. We report
that, in zebrafish, clemastine acts in vivo to enhance mycobacterial control via potentiation of the
purinergic receptor P2rx7. Using light-sheet microscopy, we find that clemastine-induced potentia-
tion of P2rx7 drives increased calcium transients within infected macrophages in vivo. P2rx7 potenti-
ation enhances inflammasome activation, resulting in restriction of mycobacterial growth in zebrafish
larvae. Finally, using a novel granuloma explant model, we show that clemastine is an effective host-
directed therapy in the context of granulomas from established mycobacterial infections.
Results
An in vivo chemical screen uncovers six novel HDTs for mycobacterial
infection
To identify novel host-directed therapies that reduce mycobacterial burden in vivo, we screened the
1200 FDA-approved drugs of the Prestwick Chemical Library using zebrafish larvae infected with
fluorescent M. marinum (Figure 1A). Three animals per well in a 96-well format were each infected
with ~ 150 CFU of M. marinum and maintained for 5 days at a 5 mM concentration of each com-
pound. We evaluated the efficacy of each of the 1200 compounds in reducing bacterial growth by
measuring mycobacterial fluorescence in whole animals over the course of a 5-day infection. Quanti-
tation of bacterial fluorescence driven by a stable, constitutive promoter provides a validated mea-
sure of bacterial burden in zebrafish larvae (Adams et al., 2011; Takaki et al., 2013; Walton et al.,
2018).
From the initial screen, we identified 51 compounds that reduced mycobacterial burden in vivo.
In a secondary screen of these potential hits, we found that 23 of the 51 compounds identified
resulted in reduced bacterial burdens in a second set of in vivo infections, and these 23 compounds
were selected for further analysis. To distinguish between drugs that directly target bacteria and
those that have host-dependent effects, we treated M. marinum cultures with each compound and
monitored bacterial growth (Figure 1A). Three compounds, each previously reported to have antimi-
crobial activity, exhibited direct anti-mycobacterial activity at the concentrations tested (Figure 1,
Figure 1—figure supplement 1A–D), validating our ability to recapitulate the effect of known anti-
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tubercular drugs in an in vivo model. A known antibiotic, sulfamethazine, was not effective at 5 mM
in broth culture, but was effective in vivo, suggesting that in vivo distribution kinetics and/or metab-
olism may enhance potency. Thus, the whole animal drug screening approach was able to identify
antibiotics that are effective in vivo but might be missed in screens of axenic cultures
(Supplementary file 1). Due to the known antimicrobial function of sulfamethazine, we did not con-
sider it further as a potential host-directed therapy. The Prestwick Chemical Library contains addi-
tional antimycobacterial agents that did not emerge as hits; however, a number of these compounds
are ineffective in zebrafish larvae at the 5 mM concentration used during our screen (Adams et al.,
2011; Takaki et al., 2013).
Because host-directed therapies may provide new approaches to TB treatment, we focused on
the subset of drugs with host-dependent activity. The 19 compounds that reduced bacterial burden
in vivo but not in culture were obtained from independent sources and tested in larger cohorts. Of
these 19 potential host-directed compounds, 9 resulted in consistently reduced bacterial burdens in
Figure 1. An in vivo zebrafish chemical screen identifies six novel host-directed therapies. (A) Schematic of chemical screen. 1200 compounds in the
Prestwick Library were screened at a final concentration of 5 mM in 0.5% DMSO for substantial reductions in bacterial burden. Three larvae were placed
in each well and imaged at 5 days post-infection (dpi). 1˚ denotes primary screen, 2˚ secondary, and 3˚ tertiary screens. Numerator represents number
of hits after that screening step over the total number of compounds tested in that step. Mm = Mycobacterium marinum (B) Hits from chemical screen
determined to reduce bacterial burden compared to DMSO control. All drug concentrations are 5 mM in 0.5% DMSO. Bacterial burden by fluorescence
is normalized to DMSO control for each experiment. Data shown is representative of three experiments with n > 15 animals for each experiment. Error
bars are s.d. *represents drugs with previously identified host-directed mechanism (C–J), Chemical structures of drugs identified as reducing bacterial
burden in a host-directed manner.
DOI: https://doi.org/10.7554/eLife.39123.002
The following figure supplement is available for figure 1:
Figure supplement 1. An in vivo zebrafish chemical screen identifies four directly antimycobacterial compounds.
DOI: https://doi.org/10.7554/eLife.39123.003
Matty et al. eLife 2019;8:e39123. DOI: https://doi.org/10.7554/eLife.39123 3 of 27
Research article Immunology and Inflammation Microbiology and Infectious Disease
three independent in vivo experiments but had no effect on bacterial growth in liquid broth culture
(Figure 1B and Figure 1—figure supplement 1). Thus, these nine drugs met all criteria for host-
dependent therapies effective in reducing burden in whole animals over 5 days of infection. One of
the nine, prothionamide, appeared to be host-dependent at the concentration tested but is likely
not host-directed (Figure 1B and Figure 1—figure supplement 1); prothionamide is a pro-drug that
can be metabolized into active anti-mycobacterial forms by both bacteria and host (Nishida and
Ortiz de Montellano, 2011).
Of the remaining eight compounds we identified as likely to be host-directed therapies
(Figure 1C–J), one drug, desipramine, had been described previously as a potential HDT; it is pro-
posed to act through inhibition of acid sphingomyelinase, which has been implicated in necroptosis
and the response to mycobacterial infection in zebrafish (Roca and Ramakrishnan, 2013). Chlor-
promazine is known to inhibit acid sphingomyelinase, although it also has reported anti-mycobacte-
rial activity in culture (Amaral et al., 2007). To the best of our knowledge, none of the six remaining
compounds had previously been considered as a potential host-directed therapy for mycobacterial
infection. We chose to focus on the most potent of these, clemastine, an inexpensive,
widely available, over-the-counter antihistamine.
Clemastine is a host-directed compound that requires host
macrophages to reduce bacterial growth
We found that clemastine consistently reduced mycobacterial growth in vivo over the course of a 5-
day infection (Figure 2A–B). The effect was dose dependent (Figure 2C), and at a concentration of
5 mM resulted in a ~ 60% reduction in bacterial burden by 5 days post-infection (dpi). At 5 dpi, there
were fewer total infection foci, and areas of infection were smaller (Figure 2B), indicating that clem-
astine reduces bacterial burden significantly after just a few days of infection. In culture conditions,
clemastine had no effect on bacterial growth at concentrations up to 50 mM, although at higher con-
centrations that were toxic to larvae (100 mM), there was some reduction in bacterial growth in cul-
ture (Figure 2D). Thus, clemastine functions to reduce bacterial burden in whole animals in a host-
dependent manner.
Clemastine’s mechanism of action was unlikely to be attributable to its antihistamine activity. Of
the 41 antihistamines in the Prestwick Chemical Library, only one other in a separate class, trimepra-
zine, was identified as a hit. In addition, diphenhydramine, another antihistamine of the same family
as clemastine, had no effect on bacterial burden (Figure 2—figure supplement 1A). Thus, we
hypothesized that clemastine’s host-directed antimycobacterial activity was due to a distinct effect
of the drug unrelated to its antihistamine activity.
Macrophages are central host cells in mycobacterial infection in humans and animal models,
including zebrafish (Clay et al., 2007; Philips and Ernst, 2012). To test whether clemastine acts via
macrophages to reduce bacterial burden, we treated infected, macrophage-deficient animals with
clemastine. Mutations in the gene encoding the myeloid transcription factor Irf8 result in an absence
of larval macrophages, due to impaired differentiation from myeloid precursors (Shiau et al., 2015).
In irf8 mutants, similar to other macrophage-deficient animals, bacterial burdens are higher, with
extracellular bacterial growth (Paga´n et al., 2015). We found that clemastine was ineffective in irf8-
deficient animals (Figure 2E–F), suggesting that clemastine’s action requires functional
macrophages.
We next took advantage of the ability to perform high-resolution, longitudinal imaging in the
zebrafish to understand how clemastine alters mycobacterial infections within macrophages in vivo.
The zebrafish infection model enables quantitation of intracellular growth in vivo through direct enu-
meration of bacterial burden and replication in individual macrophages (Takaki et al., 2013). Host
mutations that compromise the ability of macrophages to restrict intracellular mycobacterial growth
result in higher numbers of bacteria per macrophage, while bacterial mutants attenuated for intracel-
lular growth exhibit reduced bacterial numbers within each macrophage (Takaki et al., 2013). We
used a cerulean fluorescent M. marinum strain to infect the zebrafish transgenic line Tg(mfap4:tdTo-
mato)xt12 (Walton et al., 2015), in which macrophages are fluorescently labeled red, and quantified
intracellular bacterial growth during clemastine treatment (Figure 2—figure supplement 1B). Clem-
astine treatment for 24 hours reduced the number of bacteria per macrophage by ~ 30%, suggesting
that clemastine enhances control of mycobacterial infection at the level of individual infected
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Figure 2. Clemastine activity is host-dependent, dose-responsive, and requires macrophages. (A) Bacterial burden per animal assessed by Mm:
tdTomato fluorescence 5 days post infection (dpi) after treatment with 0.5% DMSO vehicle or 5 mM clemastine. Red dots denote the corresponding
image shown in Figure 2B. Representative of five experiments. (B) Representative images from experiment in Figure 2A (red dots). Mm:tdTomato
infection treated with 0.5% DMSO vehicle or 5 mM clemastine in 0.5% DMSO. White arrows denote regions of bacterial foci. Scale bar is 500 mm. (C)
Quantification of Mm:tdTomato fluorescence at 5 dpi in zebrafish larvae treated with increasing concentrations of clemastine. (D) Mm:tdTomato
bacterial broth culture grown in the presence of increasing concentrations of clemastine, compared to 0.5% DMSO, 1% DMSO, no vehicle (-), and 200
mg/mL isoniazid. (E) Bacterial burden of wildtype and heterozygous siblings or irf8st95 mutants, which lack macrophages, treated with 0.5% DMSO or 5
mM clemastine. Blue dots indicate animals in Figure 2F. Data are pooled from two biological replicates. (F) Representative infections from irf8st95
mutants and wildtype/heterozygous siblings from each treatment group in Figure 2E at 5 dpi. Wildtype animals (left) were equally brightened (no
change in gamma settings) to show contrast of bacteria and brightfield. The irf8st95-/- example animals (right) were not brightened. (G) Number of
bacteria per macrophage during treatment with 0.5% DMSO or 5 mM clemastine, 1 dpi. Each dot represents the mean number of intracellular Mm:
mCerulean bacteria inside macrophages of one Tg (mfap4:tdTomato)xt11 animal at 24 hpi infected with ~ 50 CFU. Representative of three independent
experiments. (A) Two-tailed, unpaired t-test. (C) Ordinary one-way ANOVA with Tukey’s multiple comparison test, ns1 = 0.0864, ns2 = 0.7799,
ns3 = 0.2415. Post-test for linear trend, p<0.0001. (E) Kruskal-Wallis ANOVA for unequal variances with Dunn’s multiple comparisons test, ns1 > 0.9999
Figure 2 continued on next page
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macrophages, even before formation of granulomas (Figure 2G). Importantly, clemastine did not
alter the total number of macrophages per animal (Figure 2—figure supplement 1C).
To distinguish between growth restriction and a microbicidal effect, we performed long-term live
imaging, focusing on individual macrophages within infected animals. Clemastine-treated animals
consistently showed loss of bacterial fluorescence within macrophages, while control-treated animals
did not, suggesting that clemastine enhances the microbicidal activity of macrophages (Video 1,
Figure 2—figure supplement 1D). Together, these findings are consistent with a macrophage-
dependent mechanism in which macrophage-induced mycobacterial killing is enhanced upon clem-
astine administration.
Pathogenic mycobacteria can limit acidification of the phagosome, creating a replicative niche
within macrophages (Rohde et al., 2007). We sought to determine if clemastine increased the acidi-
fication of mycobacteria-containing phagosomes. The reporter aprA’::gfp has been used to probe
acidification in mycobacteria (Abramovitch et al., 2011). The promoter of aprA is pH-inducible and
drives expression of GFP only under acidic conditions (pH <6). Simultaneous visualization of the
inducible GFP and mCherry expression from the constitutive promoter smyc (smyc’::mCherry), allows
visualization of the acidification state of bacteria in vivo. We measured the ratio of green fluores-
cence to red fluorescence in M. marinum aprA’::GFP,smyc’::mCherry infections in vivo and observed
that clemastine did not increase the proportion of bacteria that induce the aprA reporter (Figure 2—
figure supplement 1E), indicating that clemastine likely does not act through increased rates of
phagosome acidification.
Clemastine enhances calcium transients in infected macrophages, and
its activity is dependent on P2RX7
P2RX7 is a ligand-gated cation channel activated
by extracellular ATP, which is found at sites of
infection and injury (Di Virgilio et al., 2017). In
humans, mice, and fish, P2RX7 is highly
expressed on immune cells (Di Virgilio et al.,
2017; He et al., 2013). One cell culture study
had reported that clemastine can potentiate
human P2X7 receptor (P2RX7) activity
(No¨renberg et al., 2011). We hypothesized
that, in vivo, clemastine’s effect on mycobacte-
rial infection burden might involve potentiation
of P2RX7.
Using CRISPR/Cas9-based targeting, we iso-
lated and outcrossed two different alleles pre-
dicted to abolish the second transmembrane
domain of zebrafish P2RX7 receptor (P2rx7)
(Figure 3A–B). Both alleles (p2rx7xt26 and
p2rx7xt28) result in frameshifts in exon 10 and
predicted stop codons upstream of the second
transmembrane domain, suggesting that both
alleles are functional nulls (Smart et al., 2003).
We then examined whether these mutations
affected responsiveness to clemastine treatment.
Figure 2 continued
(A,C,E) Error bars are s.d. (G) Two-tailed unpaired t-test; error bars are s.e.m. p-Values from statistical tests on untransformed data are provided in
Supplementary file 2.
DOI: https://doi.org/10.7554/eLife.39123.004
The following figure supplement is available for figure 2:
Figure supplement 1. Macrophage function during clemastine treatment.
DOI: https://doi.org/10.7554/eLife.39123.005
Video 1. Clemastine treatment results in clearing of
bacteria by host macrophages. Split screen video of
the caudal hematopoietic tissue of a Tg(mfap4:
tdTomato-CAAX)xt6 (false colored magenta) zebrafish
larva infected with ~50 CFU of Mm:mCerulean. Left
side of the screen is an animal treated with 0.5%
DMSO. Right side is an animal treated with 5 mM
clemastine. In vivo timelapse is 17–34 hr post infection,
with frames every 10 min. Maximum intensity projection
of 4 z stacks of 15 mm, 30 frames per second. Stills of
single channels are in Figure 2—figure supplement
1D.
DOI: https://doi.org/10.7554/eLife.39123.006
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Given P2RX7’s known role as a calcium channel, we first assessed intracellular calcium dynamics
within macrophages in vivo during clemastine treatment.
To examine clemastine’s effect on macrophage calcium dynamics in vivo, we generated the
zebrafish transgenic line Tg(mfap4:GCaMP6F)xt25 in which the genetically encoded calcium indicator
GCaMP6F is driven by a macrophage-specific promoter (Chen et al., 2013; Walton et al., 2015).
Using light-sheet microscopy, we were able to examine macrophage calcium dynamics in whole ani-
mals in vivo during infection. Although calcium dynamics during mycobacterial infection have previ-
ously been studied in cultured macrophages, they have not been assessed in vertebrate models in
vivo. We found that both infected and uninfected macrophages in the caudal area underwent stereo-
typical calcium flashes (Figure 3C–D) at ~ 0.1 flashes per minute (Figure 3—figure supplement 1A,
Figure 3. Clemastine increases frequency of macrophage calcium transients in a p2rx7-dependent manner. (A) Schematic of P2rx7 receptor, based on
human structure, with CRISPR target site in exon 10 denoted with a star. (B) CRISPR/Cas9-mediated lesions in p2rx7 include a five base pair deletion
(p2rx7xt26) and a two base pair deletion (p2rx7xt28) leading to a premature stop codon in exon 10. Red bar denotes p2rx7 mutants and blue bar denotes
WT animals. (C) Quantification of calcium flashes observed with light-sheet microscopy in Tg(mfap4:GCaMP6F)xt25 and p2rx7xt26;Tg(mfap4:
GCaMP6F)xt25 infected with ~ 50 CFU Mm:tdTomato. Each dot represents the number of flashes observed in a single infected macrophage in an animal
during a 30-min time-course during treatment with 0.5% DMSO or 5 mM clemastine, 4–5 hpi, n > 3 fish for each group. All cells counted were visibly
infected with Mm:tdTomato and scoring performed blind to genotype or treatment. (D) Representative calcium transient. Panels are stills from a light-
sheet video in an untreated Tg(mfap4:GCaMP6F)xt25 animal infected with Mm:tdTomato. Scale bar is 25 mm. (C) Kruskal-Wallis ANOVA for unequal
variances, Dunn’s multiple comparison test. ns1 > 0.9999, ns2 = 0.7007 All error bars are s.d.; p values from statistical tests on untransformed data are
provided in Supplementary file 2.
DOI: https://doi.org/10.7554/eLife.39123.007
The following figure supplement is available for figure 3:
Figure supplement 1. Light-sheet video quantification reveals calcium dynamics in macrophages.
DOI: https://doi.org/10.7554/eLife.39123.008
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Video 2). Administration of clemastine signifi-
cantly enhanced the frequency of these macro-
phage calcium transients more than two-fold in
infected cells (Figure 3C and Video 3).
Given the known role of P2RX7 in mediating
calcium influx, we next tested whether the
enhancement of calcium transients we observed
with clemastine in vivo was dependent on
P2rx7. We crossed the macrophage calcium
reporter line into the p2rx7xt26 background
(p2rx7xt26;Tg(mfap4:GCaMP6F)xt25) and quanti-
fied calcium transients in macrophages within
whole animals by light-sheet microscopy (Vid-
eos 2–4); we observed no differences in calcium
dynamics between wildtype and p2rx7 mutant
fish at baseline (Figure 3—figure supplement
1B, Video 2). In infected wildtype animals, clem-
astine increased the frequency of calcium transi-
ents more than two-fold, but this effect was
abrogated in p2rx7 mutants (Figure 3C). Clemas-
tine did not significantly increase calcium transi-
ents in uninfected cells in infected fish
(Figure 3—figure supplement 1C). Thus, clemas-
tine’s enhancement of calcium transients in Myco-
bacterium-infected cells may occur through
potentiation, rather than direct agonism of P2rx7.
Video 2. Wildtype and p2rx7 mutants exhibit similar
calcium transients in uninfected larvae. Split screen
video of Tg(mfap4:GCaMP6F)xt25 (left) and p2rx7xt26;Tg
(mfap4:GCaMP6F)xt25 (right) uninfected larvae, 2 days
post fertilization (dpf). 30 min light-sheet microscopy
timelapse, acquiring every 8.8 s. Maximum intensity
projection of 80 steps of 1 mm, 30 frames per second.
Flashes are marked with either a circle (WT) or a square
frame (mutant). Yellow frames represent cells that only
flash once. Other colors (white, green, blue, red, green,
cyan) represent cells that flash more than once, with
the same cell marked in the same color throughout the
timelapse. Only cells that are present during the whole
video are marked. Whole cell flashes, not subcellular
flickers, are marked.
DOI: https://doi.org/10.7554/eLife.39123.009
Video 3. Clemastine enhances calcium transients in
wildtype infected zebrafish larvae. Split screen video of
Tg(mfap4:GCaMP6F)xt25larval zebrafish 2 dpf, infected
with ~ 50 CFU. Mm:TdTomato, 4 hr post infection,
treated with 0.5% DMSO (left) or 5 mM clemastine
(right). 30 min light-sheet microscopy timelapse,
acquiring every 8.8 s. Maximum intensity projection of
80 steps of 1 mm, 30 frames per second. Flashes are
marked with either a circle or a square frame. Yellow
frames represent cells that only flash once. Other colors
(white, green, blue, red, green, cyan) represent cells
that flash more than once, with the same cell marked in
the same color throughout the timelapse. Only cells
that are present during the whole video are marked.
Whole cell flashes, not subcellular flickers, are marked.
DOI: https://doi.org/10.7554/eLife.39123.010
Video 4. Clemastine does not enhance calcium
transients in p2rx7 mutant infected zebrafish larvae.
Split screen video of p2rx7xt26;Tg(mfap4:GCaMP6F)xt25
larval zebrafish two dpf, infected with ~ 50 CFU Mm:
TdTomato, 4 hr post infection, treated with 0.5%
DMSO (left) or 5 mM clemastine (right). 30 min light-
sheet microscopy timelapse, acquiring every 8.8 s.
Maximum intensity projection of 80 steps of 1 mm, 30
frames per second. Flashes are marked with either a
circle or a square frame. Yellow frames represent cells
that only flash once. Other colors (white, green, blue,
red, green, cyan) represent cells that flash more than
once, with the same cell marked in the same color
throughout the timelapse. Only cells that are present
during the whole video are marked. Whole cell flashes,
not subcellular flickers, are marked.
DOI: https://doi.org/10.7554/eLife.39123.011
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Clemastine’s anti-mycobacterial activity is dependent on p2rx7
Having established a dependence of clemastine-enhanced calcium flux on p2rx7, we next sought to
determine if the accompanying reduction in bacterial burden was also p2rx7 dependent. Using
p2rx7xt26 and p2rx7xt28 mutant larvae and wildtype siblings, we tested clemastine’s effect on bacte-
rial burden over the course of a 5-day infection. p2rx7 mutants did not show significant differences
in overall bacterial burden, although there was a slight decrease in bacterial burden in p2rx7 mutants
(Figure 4A). Clemastine consistently reduced burden in wildtype animals but failed to reduce bacte-
rial burden in p2rx7 mutants (Figure 4A–B, Figure 4—figure supplement 1A–B). Thus, both the
altered macrophage calcium dynamics and reduction in bacterial burden were dependent on func-
tional P2rx7.
Quantitation of bacterial fluorescence has been validated as an accurate measure of bacterial bur-
den in the zebrafish larval model (Adams et al., 2011; Takaki et al., 2013; Walton et al., 2018).
However, we also analyzed burden using an independent assay. We quantitated mycobacterial 16S
rRNA in a separate set of experiments and obtained similar results. Here, qRT-PCR revealed a ~ 0.5
log10 decrease with no effect in p2rx7
xt26 knockout animals (Figure 4—figure supplement 1C).
Clemastine activity requires cytosolic sensing and a functional
inflammasome
As a key second messenger, calcium is required for a variety of in vivo processes that may lead to
increased microbicidal activity, including endosomal trafficking (Fairbairn et al., 2001) and inflam-
masome activation (Ferrari et al., 2006; Murakami et al., 2012). Our previous findings on unaltered
acidification of mycobacteria in clemastine-treated animals (Figure 2—figure supplement 1E) led us
to next consider inflammasome activation as a possible mechanism.
P2RX7 signaling has been shown to promote inflammasome activation (Fairbairn et al., 2001;
Piccini et al., 2008), which can result in killing of intracellular pathogens (Ferrari et al., 2006;
Franceschini et al., 2015; Moreira-Souza et al., 2017). Activation of inflammasomes is dependent
on cytosolic sensing of PAMPs or DAMPs (Lamkanfi and Dixit, 2014). Pathogenic mycobacteria
secrete a variety of effector proteins that access the host cytosol, presumably through permeabiliza-
tion of the phagosomal membrane; cytosolic access is dependent on the specialized secretion sys-
tem ESX-1 (Conrad et al., 2017; Koo et al., 2008; Manzanillo et al., 2012; Wassermann et al.,
2015). Because P2RX7 signaling has been closely linked to inflammasome activation, we first sought
to investigate if cytosolic access is required for clemastine’s effect.
Pathogenic mycobacteria have been reported to both activate and limit inflammasome activation,
depending on the infection model used (Briken et al., 2013). Mycobacteria lacking the RD1 region,
which encompasses the ESX-1 type VII secretion system, fail to engage cytosol-based host responses
(Abdallah et al., 2011; Dorhoi et al., 2012; Volkman et al., 2004). We infected zebrafish with a M.
marinum strain lacking the RD1 region (DRD1) (Volkman et al., 2004) and asked whether clemastine
retained efficacy in the absence of engagement with the host cytosol. In contrast to its effect on
wildtype M. marinum, clemastine had no effect on burden in the DRD1 mutants (Figure 5A and Fig-
ure 5—figure supplement 1A).
As expected, M. marinum DRD1 mutants were attenuated during infection, and displayed
reduced burden at later timepoints despite equivalent inocula. We therefore wanted to rule out the
explanation that clemastine’s effect was merely dependent on burden. In order to test whether
clemastine is effective on infections with lower bacterial load, we infected larval zebrafish with a sec-
ond attenuated mycobacterial strain. We found that M. marinum transposon mutants in the gene
cmaA2, which encodes a trans-cyclopropane synthetase (Glickman et al., 2001), were attenuated in
the zebrafish model. Despite a burden comparable to the DRD1 mutants (Figure 5A and Figure 5—
figure supplement 1B), clemastine still was able to reduce bacterial load, suggesting that the RD1-
dependent effect was not merely due to differences in burden.
Reciprocally, when we increased the inoculum of DRD1 mutant bacteria above wildtype levels,
clemastine is still ineffective (Figure 5—figure supplement 1B). This was true using independent
measures of bacterial burden at five dpi including fluorescence (Figure 5—figure supplement 1B)
and 16S rRNA-based measures of burden (Figure 5—figure supplement 1C). Additionally, we
examined early control of bacterial growth in DRD1 infections. During the first 24 hr of infection,
clemastine reduced the number of WT bacteria per macrophage (Figure 2G and Figure 5—figure
Matty et al. eLife 2019;8:e39123. DOI: https://doi.org/10.7554/eLife.39123 9 of 27
Research article Immunology and Inflammation Microbiology and Infectious Disease
supplement 1D) but failed to reduce the number of bacteria per macrophage in the DRD1 infection
(Figure 5—figure supplement 1D). These data are consistent with a model in which clemastine effi-
cacy requires a host defense pathway dependent on cytosolic engagement, regardless of bacterial
load.
Given the DRD1 result, p2rx7 dependence, and the links to calcium signaling and inflammasome
activation, we next directly tested whether inflammasome activation might be required downstream
of P2rx7 activation to promote mycobacterial restriction. We focused on the common adaptor ASC,
which is required for inflammasome assembly in humans, mice, and zebrafish (Kuri et al., 2017;
Lamkanfi and Dixit, 2014). We generated asc mutant zebrafish (zebrafish gene name pycard) using
TALEN technology and generated a 14 base pair deletion allele, pycardw216, in the first exon of the
zebrafish asc orthologue (Figure 5—figure supplement 2A), resulting in a premature stop codon.
As in mice, ASC-deficient animals do not exhibit dramatically increased susceptibility to mycobacte-
rial infection (Figure 5B). Animals had similar burdens at five dpi, similar numbers of infection foci,
and displayed no gross differences during mycobacterial infection (Figure 5—figure supplement
2B). However, while clemastine reduced burden in wildtype and heterozygous sibling control ani-
mals, it was completely ineffective in zebrafish asc mutants (Figure 5B, Figure 5—figure supple-
ment 2B–C). These results are consistent with a model in which inflammasome activation may be
limited during infection with pathogenic mycobacteria, but enhancement can lead to increased bac-
terial killing.
To rule out the possibility that the clemastine effect was mediated via a previously reported con-
nection between P2RX7 and autophagy (Mawatwal et al., 2017), we tested the effect of clemastine
on autophagy in vivo during mycobacterial infection. We made use of the zebrafish reporter line Tg
Figure 4. The effect of clemastine on bacterial burden is p2rx7 dependent. (A) Quantification of Mm:tdTomato fluorescence at 5 days post-infection
(dpi) in wildtype and p2rx7xt26 larvae treated with 0.5% DMSO or 5 mM clemastine, infected with ~ 100–150 CFU. Blue bar denotes wildtype larvae and
red denotes p2rx7xt26 mutants. Red and blue dots denote the corresponding image shown in (B). Representative of 12 independent experiments,
with > 15 fish per group, presented in Figure 4—figure supplement 1A–B. (B) Representative fish from each treatment group in Figure 4A, 5 dpi.
Blue bar labels wildtype *AB fish; red bar labels p2rx7xt26. Scale bar is 500 mm. White arrows mark regions of bacterial foci. (A) Ordinary one-way
ANOVA, Tukey’s multiple comparison test, ns1 = 0.9862, ns2 = 0.5662, ns3 = 0.2451, ns4 = 0.1652, ns5 = 0.2375. All error bars are s.d.; p values from
statistical tests on untransformed data are provided in Supplementary file 2.
DOI: https://doi.org/10.7554/eLife.39123.012
The following figure supplement is available for figure 4:
Figure supplement 1. Clemastine requires functional P2rx7 to reduce bacterial burden in vivo.
DOI: https://doi.org/10.7554/eLife.39123.013
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(hCMV-GFP:Lc3) (He et al., 2009). In this line, GFP-positive puncta are indicative of autophago-
somes and can be enumerated during infection and treatment with DMSO or clemastine. Using spin-
ning disk confocal microscopy, we observed that clemastine treatment does not enhance the
number or frequency of LC3-decorated mycobacteria over the course of three days of infection (Fig-
ure 5—figure supplement 2D). These findings are in agreement with the observed lack of change
in acidification of mycobacteria, suggesting that autophagy is not the host-directed mechanism
through which clemastine reduces bacterial burden in vivo.
Clemastine is effective in established infections
We next examined whether clemastine was an effective host-directed therapy in established infec-
tions and whether it could function therapeutically in more complex, established granulomas. Adult
zebrafish granulomas share key features with human Mtb granulomas, including a caseous necrotic
core and a tight epithelialized layer that alters bacterial physiology and may restrict access to drugs
(Cronan et al., 2016; Lenaerts et al., 2015; Swaim et al., 2006). To directly examine clemastine’s
efficacy in mature, established granulomas, we made use of a novel granuloma explant model,
termed Myco-GEM (Cronan et al., 2018). Briefly, adult animals are infected and granulomas are dis-
sected after 2–4 weeks of infection and cultured ex vivo for a week. Because adult zebrafish are not
optically transparent, this explant approach allows live visualization of granuloma and bacterial
dynamics within a mature, established granuloma that contains multiple cell types. Upon multi-day
Figure 5. Clemastine efficacy requires cytosolic access and inflammasome signaling. (A) Quantification of bacterial burden of Mm:Wasabi and
MmDRD1:Wasabi in wildtype larvae treated with 0.5% DMSO or 5 mM clemastine, five dpi. Representative of three independent experiments. Each dot
represents an individual animal’s bacterial burden by fluorescence. Red dots denote the animals represented in Figure 5—figure supplement 1A. (B)
Quantification of bacterial burden of Mm:tdTomato in pycard (asc) mutants and wildtype/heterozygous siblings after 0.5% DMSO or 5 mM clemastine
treatment, 5dpi. Each dot represents an individual animal’s bacterial burden by fluorescence. Representative of three independent experiments. Blue
(WT/het) and purple (asc mutants) dots denote representative larvae in Figure 5—figure supplement 2B. Fold change over DMSO for each genotype
is presented in Figure 5—figure supplement 2C. (A) Ordinary one-way ANOVA with Tukey’s multiple comparison test. All error bars are s.d.
ns1 > 0.9999, ns2 = 0.9452, ns3 = 0.9430. (B) One-way ANOVA with Tukey’s multiple comparison test. All error bars are s.d. ns1 = 0.9998, ns2 = 0.5798,
ns3 = 0.3723. p Values from statistical tests on untransformed data are provided in Supplementary file 2.
DOI: https://doi.org/10.7554/eLife.39123.014
The following figure supplements are available for figure 5:
Figure supplement 1. Clemastine does not enhance microbicidal macrophage activities in MmDRD1 infections.
DOI: https://doi.org/10.7554/eLife.39123.015
Figure supplement 2. Clemastine requires inflammasome components to reduce bacterial burden.
DOI: https://doi.org/10.7554/eLife.39123.016
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(5–7 days) treatment with clemastine, we found a nearly 70% reduction in mycobacterial fluorescence
relative to vehicle control granulomas, suggesting that clemastine has efficacy both in established
infections (>2 weeks post infection) and in the context of a mature granuloma (Figure 6A–B and Fig-
ure 6—figure supplement 1A–B).
Consistent with the larval experiments, we found that clemastine enhanced activation of inflam-
masome-dependent pathways. We used a FLICA reagent (ImmunoChemistry Technologies) that
covalently binds a fluorophore to activated caspase-1; the fluorescent signal is a direct readout of
caspase-1 activation. Using this tool and flow-cytometry methods developed for Myco-GEM
(Cronan et al., 2018), we found that clemastine treatment significantly increased the percentage of
cells positive for FLICA relative to the DMSO control (Figure 6C, Figure 6—figure supplement 2A–
C).
To obtain an independent longitudinal readout of bacterial burden during treatment of estab-
lished infections, we constructed a bioluminescent strain of M. marinum, M. marinum:Lux
(Cronan et al., 2018). We introduced a plasmid containing a bacterial luciferase operon
(Andreu et al., 2010) into the reference strain and infected adult animals. After 2 weeks, we dis-
sected and cultured established granulomas, monitoring luminescence daily in the presence of clem-
astine or vehicle. Clemastine-treated granulomas had a nearly 10-fold reduction in luminescence
relative to control granulomas after 6 days of treatment (Figure 6D, Figure 6—figure supplement
3A), suggesting that the effect size may be greater than that observed by fluorescence-based read-
outs. To ensure that clemastine did not quench bioluminescent signals, we treated M. marinum:Lux
with clemastine in broth culture and saw no effect on luminescence compared to DMSO carrier (Fig-
ure 6—figure supplement 3B). Thus, clemastine has substantial efficacy as a host-directed therapy
both in larvae and in more complex, established granulomas.
To further validate the readout of luminescence and fluorescence in the Myco-GEM model, we
plated individual granulomas for colony forming units (CFU). We found that clemastine treatment
significantly reduced CFU by ~ 1.4 log10 (~ 27 fold) compared to vehicle-exposed granulomas after a
week of Myco-GEM culture (Figure 6E, Figure 6—figure supplement 3A).
Host-directed therapies will likely be used as adjunctive therapies in the context of antibiotic
treatment. Therefore, HDTs should not limit the effects of antibiotics and should further reduce bac-
terial load. We have previously found that moxifloxacin has reduced effectiveness against mycobac-
teria in cultured granulomas relative to mycobacteria cultured in vitro (Cronan et al., 2018). Using
granulomas infected with M. marinum:Lux, we tested clemastine’s effect in the presence of moxiflox-
acin. Clemastine treatment significantly enhanced the effect of moxifloxacin in Myco-GEM granulo-
mas (Figure 6F, Figure 6—figure supplement 3C), suggesting that it can act as a combination
host-directed therapy with other antibiotics in the context of a complex, established infection.
Discussion
One of the major causes of TB mortality is mycobacterial resistance to killing by standard antibiotics.
Humans require multi-drug regimens and prolonged duration of treatment for active disease,
increasing the risk for inadequate or discontinued treatments and the emergence of antibiotic resis-
tance. Multi-drug resistant strains (which require 9–24 months of treatment, including use of an
injectable agent) were responsible for an estimated 480,000 new TB cases in 2014, with an estimated
treatment failure rate of 46% (World Health Organization, 2018). Thus, new treatment strategies
are urgently needed.
We performed a 1200 compound chemical genetic screen of FDA-approved drugs for host-
directed therapies against mycobacterial infection using a whole animal platform. Large drug screens
in whole animals would be extremely challenging in other vertebrates, but the small size, relative
permeability, and fecundity of zebrafish enable high-throughput chemical screens.
Using the zebrafish model, we were able to identify in vivo activity of the drug clemastine on the
purinergic receptor P2rx7 during mycobacterial infection in zebrafish. We established transgenic
lines to monitor calcium dynamics within macrophages during mycobacterial infection in vivo and
found complex patterns of calcium transients. Interestingly, the frequency of calcium transients in
zebrafish macrophages is similar to what has been reported for infected Drosophila macrophages in
vivo (Weavers et al., 2016).
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Figure 6. Clemastine reduces bacterial growth in granuloma explants. (A) Representative granuloma explants treated with 5 mM clemastine or 0.5%
DMSO from wildtype or p2rx7xt26 adult animals (2 weeks post-infection) at zero days post treatment (dpt) and 5 dpt. Animals were infected with ~300
CFU Mm:mCerulean. Blue line denotes granulomas from wildtype adult fish and red line denotes granulomas from p2rx7xt26 adult fish. Images are
maximum intensity projections of spinning disk confocal images, 15 steps of 10 mm. DIC and Mm:mCerulean channels are merged. Quantification in
Figure 6—figure supplement 1A, averages from this experiment are denoted in the green squares of Figure 6B. (B) Quantification of 6 independent
experiments in which Mm:mCerluean fluorescence at 5dpt is normalized to the DMSO treatment of wildtype granuloma explants. Each dot is the
Figure 6 continued on next page
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We identified an important moonlighting activity for clemastine in mycobacterial infection: poten-
tiation of the purinergic receptor, P2RX7. That target, P2RX7, has been implicated in a variety of
inflammatory and immune processes; its activation can result in bacterial killing in cell culture (Cou-
tinho-Silva et al., 2003; Fairbairn et al., 2001; Santos et al., 2013) (reviewed in Di Virgilio et al.,
2017). Mawatwal et al have reported that calcimycin induces P2RX7 dependent autophagic killing of
M. smegmatis and BCG in cell culture (Mawatwal et al., 2017). However, we did not see enhance-
ment of autophagy in clemastine-treated animals, suggesting that this is not clemastine’s mode of
action. Intriguingly, polymorphisms in the P2RX7 receptor have been associated with TB susceptibil-
ity in humans (Li et al., 2002; Wu et al., 2014) and functional changes contribute to TB pathogene-
sis in some cell culture models but have given divergent results in different mouse models
(Amaral et al., 2014; Myers et al., 2005; Santos et al., 2013). In cell culture, P2RX7 activation
enhances mycobacterial killing in an ATP-dependent manner (Placido et al., 2006), and these find-
ings are consistent with our in vivo data with clemastine and P2RX7 activation.
Here, however, the in vivo drug screen uncovered a novel approach to modulating P2RX7 during
mycobacterial infection. While previous studies have focused on the effects of loss of function of
P2RX7, we show that direct potentiation of the channel enhances host control of infection. In addi-
tion, rather than constitutive activation, this mechanism avoids potential off-site detrimental effects.
Potentiation of an ATP-responsive channel rather than constitutive activation thus represents a more
nuanced approach to enhancing the host immune response and may avoid problems associated with
excessive or inappropriate macrophage activation (Feng et al., 2016). Supporting the notion of a
localized and infection-specific effect of the drug, only infected cells exhibited increased calcium
transients during clemastine treatment.
P2RX7 activation has been strongly linked to inflammasome activation (Di Virgilio, 2007), but
there is divergent evidence for the precise roles of inflammasome signaling during mycobacterial
infection (Briken et al., 2013; Mayer-Barber et al., 2010). In mycobacterial mutants lacking ESX-1,
there is a drastic reduction in IL-1B production in vitro, with effects on the AIM2 inflammasome
(Wassermann et al., 2015). Others have shown that non-virulent mycobacteria increase inflamma-
some activation compared to virulent strains (Shah et al., 2013). We showed that clemastine is
Figure 6 continued
average bacterial burden at 5 dpt for each treatment group, normalized to the experiment’s wildtype explants treated with DMSO. Bacterial burdens
per experiment are color-coded (e.g. red dots are all from the same experiment). Squares represent granulomas from p2rx7xt28 adult infections and
circles represent granulomas fromp2rx7xt26 adult infections. The blue line represents wildtype animals and the red line represents p2rx7 mutants. Fold
change of bacterial burden over DMSO-treated granulomas for each genotype is in Figure 6—figure supplement 1B using the same colors for each
experiment. (C) Quantification of FLICA-positive cells from FACS analysis after treatment with DMSO or 5 mM clemastine 2 dpt. Each dot represents the
treatment averages from an independent experiment, normalized to the DMSO treatment for each experiment with at least three biological replicates
per experiment. Gating strategy provided in Figure 6—figure supplement 2A and individual experimental averages in Figure 6—figure supplement
2B. (D) Quantification by luminescence of Mm:Lux granulomas 7 dpt after treatment with 0.5% DMSO or 5 mM clemastine, with each dot representing a
single experiment’s average luminescence for each treatment. Luminescence values are color-coded between experiments. Granuloma explants used
for CFU plating are colored with green dots and represented in Figure 6E as green dots. Fold change of bacterial burden over DMSO-treated
granulomas in each treatment is in Figure 6—figure supplement 3A. (E) Quantification of bacterial load by colony-forming units (CFU) 8 dpt with
DMSO or 5 mM clemastine. Each dot represents a single granuloma. Fold change of bacterial burden over DMSO-treated granulomas in each
treatment is in Figure 6—figure supplement 3A. (F) Quantification by luminescence of Mm:Lux granulomas seven dpt after treatment with 0.5%
DMSO, 5 mM clemastine, 2 mg/mL moxifloxacin, or combination clemastine and moxifloxacin. Data are pooled from two experiments. Fold change of
bacterial burden over DMSO-treated granulomas in each treatment is in Figure 6—figure supplement 3C. (B) Friedman Test (paired) ANOVA with
Dunn’s multiple comparisons test ns1 > 0.9999, ns2 = 0.1521. All error bars are s.e.m. (C) Unpaired t-test, error bars are s.e.m. (D) Paired t-test, error
bars are s.e.m. (E) Unpaired t-test, error bars are s.d. (F) Kruskal-Wallis ANOVA with Dunn’s multiple comparisons test, ns1 > 0.9999. All error bars are
s.d. p-Values from statistical tests on untransformed data are provided in Supplementary file 2.
DOI: https://doi.org/10.7554/eLife.39123.017
The following figure supplements are available for figure 6:
Figure supplement 1. Clemastine reduces bacterial growth in granuloma explants in a P2rx7 dependent manner.
DOI: https://doi.org/10.7554/eLife.39123.018
Figure supplement 2. Clemastine enhances activation of caspase-1 in granuloma explants.
DOI: https://doi.org/10.7554/eLife.39123.019
Figure supplement 3. Clemastine reduces bacterial growth in granuloma explants, as measured by luminescence and CFU-based assays.
DOI: https://doi.org/10.7554/eLife.39123.020
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ineffective against mycobacteria lacking the ESX-1 locus, leading us to initially explore the hypothe-
sis that inflammasome signaling might be required for clemastine’s effect in vivo.
To test this directly, we developed and assessed a zebrafish mutant that lacks the critical adaptor
protein Asc. Consistent with findings in mice, the zebrafish asc larvae had no significant differences
in mycobacterial burden (Mayer-Barber et al., 2010). However, mutations in other key inflamma-
some genes enhance susceptibility to mycobacterial infections in animal models, indicating that
inflammasomes can be involved in host protection (Fremond et al., 2007; Juffermans et al., 2000).
Notably, we show that clemastine is completely ineffective in inflammasome-deficient animals, sup-
porting a model in which inflammasome signaling can be host-beneficial. Thus, inflammasome activa-
tion through P2rx7 potentiation may enhance mycobacterial killing, potentially by overcoming
bacterially mediated inhibition. While excess stimulation of inflammasome signaling has also been
shown to be host-detrimental (Mishra et al., 2013), there may be differences between a more
nuanced and localized potentiation of the P2RX7 response to ATP and more general enhancement
of inflammasome activation.
As FDA-approved compounds, drugs identified using this approach have the potential to move
quickly into the clinic. Indeed, the most promising compound identified in our screen, clemastine, is
inexpensive, widely available, and has few known safety risks. Clemastine recently showed promise
in a clinical trial for patients with multiple sclerosis (Green et al., 2017), and – due to its safety pro-
file – would be a prime candidate for low-risk/high-reward studies in humans.
Clemastine is effective both in early infections in zebrafish larvae and in longer term, established
infections. Using a granuloma explant model, we found improved control of mycobacterial infection,
suggesting therapeutic efficacy in established infections and within complex granulomas, the key
host-pathogen interface in mycobacterial infections across natural host species. Taken together,
these data suggest a model (Figure 7) in which clemastine reduces intracellular bacterial burden
through potentiation of the purinergic receptor P2rx7 to induce inflammasome activation in both
nascent and established mycobacterial infections. Thus, modulation of a P2RX7 inflammasome axis is
a promising avenue for host-directed therapies against mycobacterial infection in established dis-
ease. Further understanding of the mechanistic basis for P2RX7-mediated mycobacterial control, as
well as ways in which inflammasome activation can be modulated at discrete points in infection, may
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Figure 7. A model describing clemastine as a host-directed drug against mycobacterial infection in both nascent and established infections.
Clemastine potentiates the purinergic channel, P2rx7, to increase calcium transients within infected macrophages. Clemastine enhances microbicidal
activities within macrophages to kill intracellular bacteria (A, B) in a manner that requires p2rx7 (C), intact mycobacterial ESX-1 (D), and a functional
inflammasome (E).
DOI: https://doi.org/10.7554/eLife.39123.021
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Animal handling and maintenance
All zebrafish procedures and husbandry complied with policies by the Duke University Institutional
Animal Care and Use Committee (protocol A122-17-05). Eggs were collected from in-tank spawning
and kept in 1X E3 medium (5 mM CaCl, 178 mM KCl, 328 mM CaCl2, 400 mM MgCl2 in dH2O) at
28.5˚C. Pigmentation was prevented using 1-phenyl-2-thiourea (PTU; Alfa Aesar L06690; 45 mg/mL),
beginning treatment at one dpf. Unless otherwise noted, all zebrafish are in the *AB wildtype strain.
Transgenic lines
The transgenic line Tg(mfap4:tdTomato)xt12 and Tg(mfap4:tdTomato-CAAX)xt6 have been previously
described (Walton et al., 2015). irf8st95 mutant zebrafish are described elsewhere (Shiau et al.,
2015). Creation and validation of the tnf:gfp line, (TgBAC (tnfa:GFP)pd1028) has been previously
described (Marjoram et al., 2015). The transgenic line Tg(mfap4:GCaMP6F)xt25 was made by inject-
ing Tol2 transposase mRNA and tol2-containing DNA constructs into zebrafish embryos at the one
cell stage. The constructs were assembled with Tol2kit reagents and subsequent Gateway Cloning
(Invitrogen) (Kwan et al., 2007). The 5’ element containing the mfap4 promoter, has been previously
described (Walton et al., 2015). The middle element GCaMP6F was generated by PCR amplification
of the GCaMP6F coding region from the Addgene plasmid #40755 using primers containing attB1
and attB2 sites followed by recombination into pDONR221. The 3’ element was SV40polA in
pDONR P2R-P3. The destination vector utilized was pDestTol2pA.
Generation of zebrafish lines possessing p2rx7 loss-of-function alleles
Loss-of-function alleles of p2rx7 were generated by targeting the sequence 5’- GGTTTGATGTGA
TGGTGTTTGG-3’ in exon 10 using CRISPR/Cas9 genome editing. The gRNA in vitro transcription
template was generated as described previously (Jao et al., 2013). Briefly, single-stranded DNA oli-
gos 5’-GGTTTGATGTGATGGTGTT-3’ and 5’-AAACAAACACCATCACATCAA-3’ were annealed and
inserted into the T7cas9sgRNA2 vector (Jao et al., 2013). The resulting plasmid was linearized with
BamHI (New England Biolabs R0136S), purified, and 400 ng was used as a template for in vitro tran-
scription using the T7 MEGAshortscript kit (ThermoFisher AM1354). gRNAs were co-injected with
Cas9 mRNA into single cell *AB, wildtype embryos. CRISPR/Cas9-mediated mutations were deter-
mined by HRMA (described below) and Sanger sequencing. Two alleles were maintained: a five base
pair deletion p2rx7xt26and a T to A transversion with a two base pair deletion, p2rx7xt28. Both muta-
tions cause a premature stop codon in exon 10 (Figure 3A–B). The p2rx7 mutant lines were crossed
into Tg(mfap4:GCaMP6F)xt25, Tg(mfap4:tdTomato)xt12, and Tg(mfap4:tdTomato-CAAX)xt6 and sub-
sequently homozygosed in each transgenic background. Homozygous p2rx7 mutants were viable
and exhibited no apparent anatomical or fertility defects. asc/pycard loss-of-function alleles were
generated by TALEN-mediated targeting (Dahlem et al., 2012) of pycard exon 1, resulting in a 14
base pair deletion in the PYRIN domain (Figure 5—figure supplement 2A). pycard mutant animals
are viable as adults and of similar size and fecundity.
Characterization and maintenance of cmaA2 transposon mutant M.
marinum
Identification of transposon insertion sites
Two transposon mutants with disruptions in the cmaA2 ORF, designated cmaA2Tn01901 and
cmaA2Tn02791, were identified from a sequenced library of M. marinum transposon mutants (C.
Cosma and L. Ramakrishnan). The previously identified insertion sites were confirmed by semi-
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random PCR and sequencing, using a pool of semi-random primers in conjunction with a pair of
nested primers annealing within the 3’ end of the transposon. Primer sequences are as follows:
Semi-random pool: 5’-GCAACNNNNGTCTCGTTAGCTCGCTGGCC-3’; 5’-ATATCNNNNGTCTCG
TTAGCTCGCTGGCC-3’; and 5’-GTACTNNNNGTCTCGTTAGCTCGCTGGCC-3’, where N denotes
random nucleotide insertion during primer synthesis (Integrated DNA Technologies). Outer transpo-
son-specific primer (TnMarR3): 5’-ACAACAAAGCTCTCACCAACCGTG-3’; Inner transposon-specific
primer (TnMarR2): 5’-CAGACACTGCTTGTCCGATATTTGATTTAGG-3’.
The semi-random primer pool and TnMarR3 were used to perform an initial, unbiased amplifica-
tion of a region around any possible transposon insertion junctions. A second amplification was then
performed using a primer corresponding to the constant region of the semi-random pool (5’-GTC
TCGTTAGCTCGCTGGCC-3’) and TnMarR2. The product of the second amplification was sequenced
using TnMarR2, and the output was aligned to the M. marinum genome (BLASTn, NIH). The pres-
ence of a single sequence aligning to the cmaA2 locus confirmed the presence of only a single trans-
poson insertion in each genome and disruption of the cmaA2 ORF for both cmaA2Tn01901 and
cmaA2Tn02791. The insertion site for cmaA2Tn01901 is located ~ 14% into the ORF between the first
and second bases of the 42nd codon. The insertion site for cmaA2Tn01901 is located ~ 75% into the
ORF between the second and third bases of the 230th codon. CmaA2Tn01901 (Tn01901) was selected
for further study.
Generation of fluorescent transposon mutant strains
The mutants possess the TnMar transposon, conferring resistance to Hygromycin B. Fluorescent
strains were generated by electroporating (800 W, 25 mF, 2.5 kV, 0.2 cm gap) msp12:mCerulean-
KanR (a gift from L. Ramakrishnan, University of Cambridge) into either mutant strain. Selection on
media containing Kanamycin (20 mg/ml) and Hygromycin B (50 mg/ml) yielded mutant clones
expressing the mCerulean fluorescent protein.
Bacterial preparations
Wild-type Mycobacterium marinum (M. marinum) constitutively expressing a fluorescent protein
(tdTomato, mCerulean, or Wasabi) and a Hygromycin resistance cassette driven by the msp12 pro-
moter were grown to late log phase (OD600 = 0.8) at 33˚C in liquid 7H9 complete media (Middle-
brook 7H9 base, Difco BD 271310) supplemented to a final concentration of 10% OADC (50 g/L
BSA, 0.5% oleic acid, 20 g/L dextrose, 8.5 g/L NaCl), 0.05% Tween-80 (Fisher BP338-500), and 50
ug/mL Hygromycin B (Sigma H0654). M. marinum DRD1 was a gift from Lalita Ramakrishnan
(Volkman et al., 2004). Bacteria were prepared into single-cell suspensions, as described
(Takaki et al., 2013). Single-cell suspension aliquots were diluted to approximately 1  108 cfu/mL
in 5 mL 7H9 media + OADC and were stored at  80˚C long-term and diluted in 7H9 to an appropri-
ate concentration prior to injection.
Bacterial broth growth assay
Wild-type M. marinum expressing tdTomato was grown to OD600 = 0.8 and then diluted 1:10 in 7H9
complete media supplemented with 50 ug/mL Hygromycin B in 15 mL culture tubes (Falcon). The
bacterial culture was supplemented with 0.5% DMSO (MPI), 200 mg/mL Isoniazid (Sigma-Aldrich
I3377), 10 mg/mL moxifloxacin (Matrix Scientific 047902) or 5 mM of each chemical and grown in a
33˚C shaker for 7–8 days. Each day, 100 mL of the broth was placed in a cell culture 96-well micro-
plate plate (GBO 655090) and analyzed with an Enspire 2300 Multilabel Plate Reader (PerkinElmer)
for OD600 and fluorescence intensity, with three technical replicates per sample. The same methods
were used for a growth curve in the presence of clemastine (Sigma, SML0445) for both M. marinum
expressing mCerulean and M. marinum DRD1 expressing tdTomato (data not shown).
Larval zebrafish infection
Two dpf larvae were anaesthetized with tricaine (MS-222; Sigma-Aldrich 160 mg/ml) and injected
with fluorescent M. marinum. Single-cell suspension aliquots are diluted in 7H9 with 0.5% phenol red
indicator (Sigma 0290) prior to injection. Between 50 and 200 CFU of fluorescent M. marinum were
injected using a borosilicate needle (Sutter Instruments BF100-58-10), pulled with a WPI PUL-1000
system (factor setting 0) and broken approximately 8 mm from the tip. Injections are performed
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using a FemtoJet injector (Eppendorf). After infection, larvae were recovered in E3 +PTU for 4 hr at
28˚C. For examination of mutant phenotypes, infections were performed blind to larval genotype.
Drug treatments
Four hours post-infection, larvae were transferred to wells containing E3 + PTU supplemented with
the compound being tested. For most studies, larvae were kept in six-well plates (COSTAR 3736)
containing E3 + PTU supplemented with either 0.5% DMSO (MP Bio CAS 67-68-5) or 5 mM clemas-
tine fumarate (Sigma-Aldrich SML0445) dissolved in 100% DMSO to a final concentration of 0.5%
DMSO in each treatment group. Diphenhydramine hydrochloride (Sigma-Aldrich D3630) was dis-
solved in 100% DMSO and diluted to a final concentration of 5 mM. All drugs were added directly to
E3 + PTU. Whenever agarose was used to mount fish, the same concentration of drug was added to
the agarose prior to solidification.
Live imaging and quantification of bacterial burden
Epifluorescence microscopy was carried out on an inverted Zeiss Observer Z1 microscope using
2.5X, 5X, or 20X objectives, depending on experiment. Prior to imaging, larvae were anaesthetized
with tricaine (160 mg/ml) and arrayed on a microscope slide or embedded in 0.75% low melting
point agarose (Fisher BP165) in a 35 mm petri dish (MatTek). Bacterial burden by fluorescence is cal-
culated using ImageJ (Rueden et al., 2017). Images are analyzed for the mean fluorescence and
area of fluorescence above a threshold within the zebrafish. The threshold is empirically determined
for each experiment to ensure that every infected animal has a non-zero value while not including
any background autofluorescence. The threshold is kept constant between treatments within an
experiment. The product of the mean fluorescence and area is computed and presented as ‘Mm
Fluorescence.’ Granuloma explants were visualized on a spinning disk confocal (Andor) using 10x/0.3
UPlanFl N dry, WD: 10 mm, FN26.5, UIS2 objective, acquiring images with an Andor Ixon3 897 512
EMCCD, 1.2x auxilary magnification camera. Z stacks were taken at 10–15 mm, and images are
assembled as maximum intensity projections using ImageJ (Rueden et al., 2017). During image
analysis, experimenter was blinded to the genotype of the larvae.
Light-sheet microscopy
Light-sheet fluorescence microscopy experiments were carried out on a Zeiss Light-sheet Z.1 using a
Plan-Apochromat 20X/1.0 NA Aqueous immersion objective, situated with a C.mos PCO.edge cam-
era with 16bit 1920  1920 sensors. One track, emission selection: 488/498 (GFP) and 560/571
(tdTomato). Light-sheet thickness was 4.32 microns with a continuous drive, 1x zoom, dual side illu-
mination. For these experiments, two dpf zebrafish larvae Tg(mfap4:GCaMP6F)xt25 and p2rx7xt26;Tg
(mfap4:GCaMP6F)xt25 were infected as described and treated with DMSO or clemastine at four hpi.
One to 2 hr post-treatment, larvae were placed in 1.5% low-melting point agarose, supplemented
with 80 mg/ml tricaine and either 0.5% DMSO or 5 mM clemastine fumarate (Sigma-Aldrich
SML0445) in a 3 mm OD glass capillary. A dual-colored z-stack was acquired every 8.8 s, collecting
80 z-steps, using a z-step size of 1 mm for 30 min.
Light-sheet videos were projected as maximum intensities and analyzed using ImageJ
(Rueden et al., 2017). Regions of interest (ROIs) were defined as single macrophages that expressed
baseline levels of green fluorescence by GCaMP6 and flashed at least once over the course of the
video. Macrophages outside of the caudal hematopoietic tissue were excluded. Only individual
flashes were counted, not coordinated flashes during which every macrophage, infected and unin-
fected, underwent a calcium flash simultaneously. If the macrophage was not in frame for the entire
30 min, it was not included in the analysis. Quantitative analyses of macrophage calcium flashes
were performed blind to the treatment type and genetic identity of the specimens under
observation.
Adult infections and granuloma explants
Adult zebrafish (>2 months old) were infected as described (Oehlers et al., 2015). Briefly, adult fish
(>2 months old) were anesthetized by immersion in 100 mg/mL tricaine and injected intraperitoneally
with 300 CFU of Mm:mCerulean or Mm:tdTomato using insulin needles (BD 08290-3284-38). Adult
fish were kept in 1L tanks in a dedicated infection incubator with light/dark cycles at 28˚C, with water
Matty et al. eLife 2019;8:e39123. DOI: https://doi.org/10.7554/eLife.39123 19 of 27
Research article Immunology and Inflammation Microbiology and Infectious Disease
changes and feeding every day. Between two and four weeks post-infection, granulomas were har-
vested using a Myco-GEM method (Cronan et al., 2018). Briefly, after adult fish are euthanized with
a lethal dose of tricaine, the body cavity is exposed in sterile L15 medium (Gibco 21083–027). Granu-
lomas can be dissected out with forceps or gently removed by a glass pipette. Granulomas are seri-
ally washed in sterile L15 and size-matched for treatment groups. The bottom of an optical-bottom
96-well plate (GBO 55090) is covered with 40 mL of 5 mg/mL Matrigel Matrix (Corning 354262), in
L15. Granulomas are embedded in 2.5-dimensional top media with a final concentration of 5% FBS
(Sigma 2442), and 1 mg/mL Matrigel matrix (Corning 354262) in L15 (Gibco 21083–027) as described
(Cronan et al., 2018). The top and bottom media are supplemented with either DMSO (0.5%) or
clemastine (5 mM in 0.5% DMSO). Granulomas are imaged via microscopy at d0 and 5 days post-
treatment (dpt) using epifluorescence microscopy on an inverted Zeiss Observer Z1 microscope and
on a spinning disk confocal (Andor). M. marinum:Lux granulomas were imaged daily as described
below. Image acquisition and analyses were performed blind to the genotype of the granulomas.
Bioluminescence assay
For this assay, we used a bioluminescent reporter strain of M. marinum (Mm-Lux) as described in
Cronan et al. (2018). Adult zebrafish were infected as described above and granuloma explants cul-
tured in the same methods as described above but were kept in white 96-well cell culture micro-
plates (GBO 675098) and luminescence was determined using an EnSpire 2300 Multilabel Plate
Reader obtained from Perkin Elmer (Waltham, MA). Drug treatments were applied in the same fash-
ion as fluorescence assays, with drug added to both bottom media and top media.
Flow cytometry and FLICA staining of granuloma explants
For all flow cytometry experiments, we cultured granuloma explants as described above for 48 hr in
the presence of 0.5% DMSO or 5 mM clemastine. Granulomas were rinsed in sterile L15 and PBS.
Following manufacturer’s directions, 660-FLICA Caspase Assay (Immunochemistry Technologies
ICT097) was reconstituted with 50 mL 100% DMSO to make 150X stock. This stock was aliquoted
into single use tubes and kept at  20˚C and not freeze-thawed more than once. Just prior to use,
the 150X stock was diluted 1:5 in PBS to make 30X stock. Grouped granulomas (~10 per group)
were placed in 1.5 mL tubes with 97 mL PBS and 3 mL of 30  660 FLICA stock. Granulomas were
kept at 28˚C for 1 hr. Granulomas were washed in 1X apoptosis buffer and spun at 1200xg for 1 min
three times. Granulomas were resuspended in 1 mL 0.05% trypsin in 1X EDTA (ThermoFisher Scien-
tific, 25300) and kept on a nutator for 40 min at 30˚C. Granulomas were centrifuged for 5 min at
300xg and rinsed with 1 mL 5% FBS in PBS three times, gently pipetting off supernatant each time,
resuspended in 300 mL 5%FBS in PBS and pipetted over a 30 mm cell strainer (MACS Miltenyi 130-
098-458). Single cell suspensions were analyzed on a FACS Canto II (BD Biosciences) using an Apc-
Cy7 laser (633 nm) excitation. Data was collected using FACSDiva Software (BD Biosciences) and
analyzed using FlowJo v10 (Treestar).
Colony-forming unit (CFU) assay on granuloma explants
Granulomas were cultured as described above for up to a week. On the final day of treatment, indi-
vidual granulomas were washed in sterile PBS, as in Cronan et al. (2018). Briefly, individual granulo-
mas were homogenized in sterile 7H9 media in a microcentrifuge tube with two sterile glass beads.
Homogenates were diluted incrementally to 10 6 and plated on 7H10 media (BD Difco 262710) sup-
plemented with 20 mg/mL kanamycin (Sigma-Aldrich K0129). Plates were incubated for 12–14 days
at 30˚C.
Prestwick chemical library screen
The Prestwick Chemical Library (Prestwick Chemical, Illkirch, France) was stored at  80˚C at 10 mM
and aliquoted manually into 1 mM working stock daughter plates in 100% DMSO. The daughter
plates were stored at  20˚C until used in 96-well format. Wildtype zebrafish larvae carrying a TNF
reporter transgene (Tg(BAC(tnfa:GFP)pd1028) (Marjoram et al., 2015) were arrayed in 96-well optical
plates (GBO 655090) with three infected and one uninfected fish per well, in 200 mL of E3 + PTU and
5 mM of each chemical. First and last rows of each plate were maintained as 0.5% DMSO controls.
Each plate contained 80 drugs, with 15 plates in all. Burden was assayed by fluorescence area and
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mean intensity of fluorescent mycobacteria at five dpi. In the secondary screen, hits were screened
again in the same format (three infected fish, one uninfected fish) and drugs that continued to
reduce bacterial fluorescence area and mean intensity were tested again in a tertiary screen with 20
fish per group, with DMSO-treated fish as control.
Determination of relative M. marinum burden by 16S rRNA qRT-PCR
Total RNA was isolated from each group of larvae using TRIzol Reagent (Thermo Fisher Scientific
15596026). An input mass of 1 mg of RNA per group was used for cDNA synthesis using the iScript
cDNA Synthesis Kit (Bio-Rad 1708890). Average relative bacterial burdens were quantified by qPCR
(Power SYBR Green PCR Master Mix, Thermo Fisher Scientific 4368577) targeting the M. marinum
16S locus. F primer: 5’-CGATCTGCCCTGCACTTC-3’; R primer: 5’-CCACAGGACATGAATCCCGT-
3’. Zebrafish b-actin transcript levels were used as the internal input control. F primer: 5’-CGAGCAG-
GAGATGGGAACC-3’; R primer: 5’-CAACGGAAACGCTCATTGC-3’ (Walton et al., 2018).
Genotyping assays
All genotyping assays were performed on fin-clips from adult zebrafish or post-experiment on whole
larval animals, using genomic DNA isolated as described (Meeker et al., 2007). p2rx7xt26 and
p2rx7xt28 were genotyped via KASP assays (LGC Genomics, Middlesex UK). pycardw216 mutant lar-
vae were genotyped using HRMA (Applied Biosystems MeltDoctor HRM 4415440). irf8 mutations
were genotyped using PCR amplification and AvaI restriction digest, as described (Shiau et al.,
2015). Additionally, HRMA primers were developed to more rapidly genotype irf8 mutant fish. All
initial mutations were confirmed via Sanger sequencing.













All statistics were performed using Prism (GraphPad), version 7. Statistics presented are performed
on data presented for each graph (e.g. if a graph displays y=log10(y) transformation, then the
p values are from a statistical test on that data). All p values from statistical tests performed on trans-
formed and untransformed data are provided in Supplementary files 2 and 3.
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. Supplementary file 1. Summary of identified compounds. Compounds with blue background are
host directed and compounds in red are known anti-infectives. Asterisk (*) represents compounds
with previously identified host-directed anti-mycobacterial activities.
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. Supplementary file 2. Summary of p values and statistical tests for Figures 1–6. Statistics per-
formed on transformed data are in yellow and untransformed is in gray. The table is organized by
figure number, in chronological order. Statistical tests are listed and transformation equation
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provided, where applicable. When a paired t-test is performed on paired data, the results of the
unpaired t-test are also given. When both paired and unpaired are potentially appropriate (in the
case of paired data with ineffective pairing), both test results are given. Statistical test results in
italics denote tests not presented within the figures.
DOI: https://doi.org/10.7554/eLife.39123.023
. Supplementary file 3. Summary of p values and statistical tests for the figure supplements to Fig-
ures 1-6. Statistics performed on transformed data are in orange and untransformed is in light blue.
The table is organized by figure number, in chronological order. Statistical tests are listed and trans-
formation equation provided, where applicable. When a paired t-test is performed on paired data,
the results of the unpaired t-test are also given. When both paired and unpaired are potentially
appropriate (in the case of paired data with ineffective pairing), both test results are given. Statistical
test results in italics denote tests not presented within the figure.
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